Dtsch Med Wochenschr 2014; 139(06): 268-271
DOI: 10.1055/s-0033-1359998
Rheumatologie | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie der rheumatoiden Arthritis: Wie wird das Risiko für Infektionen und Malignome beeinflusst?

Therapy of rheumatoid arthritis: what influences the risk of infections and malignant neoplasms?
C. Fiehn
1   ACURA-Rheumazentrum Baden-Baden
› Author Affiliations
Further Information

Publication History

Publication Date:
28 January 2014 (online)

    Permissions and Reprints

Schlüsselwörter

rheumatoide Arthritis - Risikoeinschätzung - Infektionen - Malignome

Keywords

rheumatoid arthritis - risk assessment - infections - malignant diseases
 

  • Literatur

  • 1 Baecklund E, Ekbom A, Sparen P et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180-181
    Google Scholar
  • 2 Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-460
    CrossrefGoogle Scholar
  • 3 Dixon WG, Watson KD, Lunt M et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010; 62: 755-763
    CrossrefPubMedGoogle Scholar
  • 4 Doran MF, Crowson CS, Pond GR et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-2300
    CrossrefGoogle Scholar
  • 5 European Medicines Agency (EMA). Refusal of the marketing authorisation for Xeljanz (tofacitinib) EMA/460814/2013. 26.07.2013. http://www.ema.europa.eu/docs/en_GB/ document_library/ Summary_of_opinion_-_Initial_authorisation/human/002542/ WC500146629.pdf
    Google Scholar
  • 6 FDA. FDA news release: FDA approves Xeljanz for rheumatoid arthritis. 06.11.2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm
    Google Scholar
  • 7 FDA. FDA-Advisory Committee Meeting: Tofacitinib for the treatment or rheumatoid arthritis. NDA 203214. 09.05.2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf
    Google Scholar
  • 8 Fiehn C. Rheumatoide Arthritis: das kardiovaskuläre Risiko ist hoch, aber beeinflussbar. Dtsch Med Wochenschr 2013; 138: 202-204
    Article in Thieme ConnectGoogle Scholar
  • 9 Gottenberg J-E, Duzanski MO, Bardin T et al. Tolerance of rituximab in patients with a history of cancer: data from the registry air. Arthritis Rheum 2012; 64 (Suppl. 10) S564
    Google Scholar
  • 10 Le Blay P, Mouterde G, Barnetche T et al. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol 2012; 30: 756-764
    Google Scholar
  • 11 Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013; 52: 53-61
    CrossrefPubMedGoogle Scholar
  • 12 Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013; 52: 53-61
    CrossrefPubMedGoogle Scholar
  • 13 Mikuls TR, Saag KG, Criswell LA et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002; 61: 994-999
    CrossrefGoogle Scholar
  • 14 Raaschou P, Simard JF, Holmqvist M et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013; 346: f1939
    CrossrefGoogle Scholar
  • 15 Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624
    CrossrefGoogle Scholar
  • 16 Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64: 625-639
    CrossrefGoogle Scholar
  • 17 Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70: 1914-1920
    CrossrefGoogle Scholar
  • 18 Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-744
    CrossrefGoogle Scholar
  • 19 van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519
    CrossrefGoogle Scholar
  • 20 Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-494
    CrossrefPubMedGoogle Scholar
  • 21 Zink A, Manger B, Kaufmann J et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2013; Jun 28. [Epub ahead of print]
    Google Scholar